However, we did not find significant evidence supporting associations of the APOE 22 (OR 1.15, 95% CI: 0.45-2.93), APOE 23 (OR 0.84, 95% CI: 0.64-1.09), or APOE 24 (OR 1.40, 95% CI: 0.70-2.77) genotypes, nor the APOE 2 (OR 1.02, 95% CI: 0.73-1.42) or APOE 3 (OR 0.82, 95% CI: 0.65-1.02) alleles with CJD using a fixed-effects model.
Our results do not support the contention that the APOE epsilon4 allele is a risk factor for developing Creutzfeldt-Jakob disease or related disorders.
Patients with definite CJD had a mean (SD) Apo E concentration of 3.4 (2.0) mg/L; patients with probable CJD, 3.1 (1.6) mg/L; patients with possible CJD, 3.8 (2.2) mg/L; and subjects with other diseases, 3.0 (1.7) mg/L.
These two subjects, both homozygous for the APOE-epsilon4 allele, were primarily diagnosed as having Creutzfeldt-Jakob disease and Pick's disease in the absence of significant neocortical amyloid deposition.
We analyzed apolipoprotein E (apo E) genotypes in 53 Japanese sporadic Creutzfeldt-Jakob disease (CJD) patients and 100 normal controls using the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods.
The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies.